View in EDS PDF Full Text

Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Saved in:
Bibliographic Details
Title: Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Authors: Parimi S; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada., Eliasziw M; Tufts University, Boston, MA, USA., North S; Cross Cancer Institute, Edmonton, AB, Canada., Trudeau M; Medicine Hat Cancer Centre, Medicine Hat, AB, Canada., Winquist E; London Regional Cancer Centre, London, ON, Canada., Chi KN; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada., Ruether D; Tom Baker Cancer Centre, Calgary, AB, Canada., Cheng T; Tom Baker Cancer Centre, Calgary, AB, Canada., Eigl BJ; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Bernie.Eigl@bccancer.bc.ca.
Source: Investigational new drugs [Invest New Drugs] 2016 Dec; Vol. 34 (6), pp. 771-776. Date of Electronic Publication: 2016 Aug 26.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 27565809
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Parimi+S%22">Parimi S</searchLink>; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.<br /><searchLink fieldCode="AU" term="%22Eliasziw+M%22">Eliasziw M</searchLink>; Tufts University, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22North+S%22">North S</searchLink>; Cross Cancer Institute, Edmonton, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Trudeau+M%22">Trudeau M</searchLink>; Medicine Hat Cancer Centre, Medicine Hat, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Winquist+E%22">Winquist E</searchLink>; London Regional Cancer Centre, London, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Chi+KN%22">Chi KN</searchLink>; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.<br /><searchLink fieldCode="AU" term="%22Ruether+D%22">Ruether D</searchLink>; Tom Baker Cancer Centre, Calgary, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Cheng+T%22">Cheng T</searchLink>; Tom Baker Cancer Centre, Calgary, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Eigl+BJ%22">Eigl BJ</searchLink>; Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Bernie.Eigl@bccancer.bc.ca.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2016 Dec; Vol. 34 (6), pp. 771-776. <i>Date of Electronic Publication: </i>2016 Aug 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=27565809
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-016-0386-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 771
    Titles:
      – TitleFull: Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Parimi S
      – PersonEntity:
          Name:
            NameFull: Eliasziw M
      – PersonEntity:
          Name:
            NameFull: North S
      – PersonEntity:
          Name:
            NameFull: Trudeau M
      – PersonEntity:
          Name:
            NameFull: Winquist E
      – PersonEntity:
          Name:
            NameFull: Chi KN
      – PersonEntity:
          Name:
            NameFull: Ruether D
      – PersonEntity:
          Name:
            NameFull: Cheng T
      – PersonEntity:
          Name:
            NameFull: Eigl BJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2016 Dec
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1